<DOC>
	<DOCNO>NCT02559440</DOCNO>
	<brief_summary>The purpose study determine effect MF/OXY treatment adenoid hypertrophy child severe allergic rhinitis .</brief_summary>
	<brief_title>Mometasone Furoate Oxymetazoline Treatment Adenoid Hypertrophy</brief_title>
	<detailed_description>The investigator perform two stage , parallel , randomize , double-blind , double-dummy , clinical trial 240 AH child concomitant perennial allergic rhinitis . In first treatment stage , 240 child assign MF ( 50μg , 1 puff nostril every evening ) control group ( normal saline ) two week 's run-in period . After 6 week 's treatment , child MF group evaluate grouped responder non-responders accord subjective symptom objective performance . Responders follow six month reassess . Non-responders underwent 2-week washout period randomly assign 4 group receive follow treatment : placebo , OXY ( 0.05 % , 1 puff nostril every evening ) MF ( 50μg , 1 puff nostril every evening ) . All participant receive 8 week ' MF placebo plus one week 's OXY placebo every second week . After , patient follow six month evaluation do different time point .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<criteria>adenoid occlude least 75 % nasopharynx nasal endoscopy age 5 11 year chronic obstructive nasal symptom less 12 month moderatetosevere AR tonsillar hypertrophy upper respiratory infection within last 2 week sinonasal anatomic anomaly diseases craniofacial malformation genetic disease ( i.e. , Down 's syndrome ) neurologic cardiovascular disease immunodeficiency history epistaxis asthma hypersensitivity MF OXY undergo intranasal , topical , systemic steroid antibiotic treatment within past 4 week</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>